Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Autobahn Therapeutics

Request full access

Focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body

San Diego, United StatesFounded 2018Biotech & Life Sciences

About Autobahn Therapeutics

Autobahn Therapeutics is a biopharmaceutical startup that operates in the healthcare sector, specifically focusing on the development of innovative therapies for central nervous system (CNS) disorders. The company's mission is to improve the health and quality of life for people affected by these disorders by harnessing the regenerative power of the human body.

The company's business model revolves around the development and commercialization of its proprietary brain-targeting chemistry platform. This platform enables the creation of orally administered small molecule prodrugs, which are drugs that are metabolized into pharmacologically active compounds in the body. These prodrugs have tunable ratios of central versus peripheral exposure, allowing for the development of molecules with distribution profiles tailored to match the pathophysiology of specific diseases.

Autobahn Therapeutics serves a broad market of patients affected by CNS disorders, a group that includes conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis, among others. The company generates revenue through the development, clinical testing, and eventual commercialization of its therapeutic products.

The company's portfolio is anchored by programs that leverage established clinical precedence, human genetics, and biology. This approach helps to de-risk their pipeline and accelerate early development. The company also utilizes biomarker-driven development strategies to demonstrate on-target/on-tissue activity and proof-of-mechanism early in the clinic.

Source: Dealroom company data

At a glance

Status
Operational
Employees
35
Open positions
None listed
Dealroom signal
80.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Neurology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B, B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jul 2024 $100M $400M Invus · BVF Partners · Section 32 · Samsara BioCapital ↗
LATE VCOther financing Sep 2022 $33M $380M Bristol-Myers Squibb · ARCH Venture Partners · BVF Partners · GT Healthcare ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Autobahn Therapeutics website traffic

Latest recorded traffic for Autobahn Therapeutics is 2.8K monthly website visits, up 33.3% over the last three months. Autobahn Therapeutics's team grew 0% over the past year.

Latest monthly visits2.8K 3-month web change+33.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Autobahn Therapeutics in the San Diego ecosystem

Live from Dealroom

The Autobahn Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • ARCH Venture Partners
  • Cowen Group
  • Bristol-Myers Squibb
  • BVF Partners
  • Pfizer Ventures
  • Biogen
  • Invus
  • Alexandria Venture Investments
  • Section 32
  • Samsara BioCapital

Series B and later6 investors entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Autobahn Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.